Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaKorai 1. fázis

The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar Type

A legfontosabb adatok

Ki végzi
yilong Wang
Hol
Beijing (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
Korai 1. fázis
Résztvevők
20 fő, tervezett
Kezdés
2026. jún. 10.
Várható befejezés
2027. okt. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • ALT001
A regiszteradat frissítve
2026. szeptember 9.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with multiple system atrophy of the cerebellar type (MSA-C), a brain disease that affects balance and movement. It tests the safety of ALT001 and whether it may help.

Életkor
30 to 75 years
Nem
All sexes
A betegség stádiuma
Clinically established or clinically probable MSA-C by the 2022 MDS criteria. Movement symptoms, including ataxia (poor coordination), for no longer than 5 years. Score ≤ 3 on Item 14 of UMSARS Part II. Expected to live at least 1 year.
Korábbi kezelés
No other trial treatment or investigational drug within the past 1 month or 5 half-lives. No vaccination within the past 1 month.

A részvétel fő kizáró okai

  • Other causes of ataxia, dementia, or other brain diseases seen on MRI
  • Past cancer or current anti-cancer drugs; epilepsy or anti-epileptic drugs
  • Cannot have a lumbar puncture or MRI, or has blood clotting problems
  • Severe liver, kidney or heart problems; active hepatitis B, hepatitis C or HIV
  • Pregnant, breastfeeding, able to become pregnant, or planning a pregnancy

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • 1. Age between 30 and 75 years inclusive, either sex
  • 2. Clinically established or clinically probable MSA-C as defined by the 2022 MDS diagnostic criteria for multiple system atrophy
  • 3. Duration of MSA-C-related motor symptoms, including ataxia, no longer than 5 years
  • 4. Score ≤ 3 on Item 14 of the Unified Multiple System Atrophy Rating Scale (UMSARS) Part II (motor examination)
  • 5. Estimated life expectancy ≥ 1 year as assessed by the investigator
  • 6. Voluntary participation in this study and provision of written informed consent

Ki nem vehet részt

  • 2. Dementia indicated by the Mini-Mental State Examination (MMSE) at enrollment (score ≤17 for illiterate individuals, ≤20 for primary school education, or ≤24 for junior high school or above) or a prior definitive diagnosis of dementia
  • 4. Presence of immune-mediated diseases that are inadequately controlled or require treatment with biologic agents
  • 7. Patients with a prior definitive diagnosis of malignancy or those currently receiving anti-tumor drug therapy
  • 8. Patients with a prior definitive diagnosis of epilepsy or those currently taking anti-epileptic drugs
  • 19. Current participation in other interventional trials or use of other investigational biologic agents, drugs, or devices, or use of other investigational drugs within the past 1 month or within 5 half-lives of the drug
  • 1. Presence of other diseases that may cause ataxia at screening (e.g., infectious diseases, immune-mediated diseases, tumors, paraneoplastic conditions, hereditary disorders, trauma, nutritional deficiencies, toxic exposure, or other neurodegenerative diseases)
  • 3. Evidence of other central nervous system pathologies on brain MRI at screening suggesting a diagnosis of neurodegenerative diseases other than MSA; or other significant pathological findings on brain MRI at screening, including but not limited to: cerebral hemorrhage, acute cerebral infarction, aneurysm, vascular malformation, infectious lesions, brain tumors, or other space-occupying lesions (meningiomas or arachnoid cysts with a maximum diameter <1 cm do not require exclusion)
  • 5. Known history of allergies to biologic agents, such as proteins or cell-based products
  • 9. Presence of lumbar spine diseases or deformities, or other contraindications to lumbar puncture
  • 11. Contraindications to MRI (e.g., claustrophobia, implanted cardiac pacemaker, or ferromagnetic metal)
  • 14. Positive for hepatitis C virus antibody or a history of positive test results
  • 15. Positive for HIV or a history of positive test results
  • 16. Patients with a history of alcohol or substance abuse, or alcohol or substance dependence within the past 2 years
  • 17. Diagnosis of psychiatric disorders, severe anxiety, severe depression, or obvious suicidal ideation according to DSM-V diagnostic criteria
  • 10. Coagulation abnormalities at enrollment (e.g., platelet count <100 × 10⁹/L; prothrombin time [PT] >3 seconds), a prior diagnosis of coagulation disorders such as hemophilia, or current use of two or more antiplatelet agents
  • 12. Concurrent severe hepatic insufficiency, renal insufficiency, or severe cardiac insufficiency (severe hepatic insufficiency defined as ALT ≥1.5 times the upper limit of normal or AST ≥1.5 times the upper limit of normal; severe renal insufficiency defined as serum creatinine [CRE] ≥1.5 times the upper limit of normal or estimated glomerular filtration rate [eGFR] <40 mL/min/1.73 m²; severe cardiac insufficiency defined as NYHA class 3-4), or any significant abnormalities on physical examination, vital signs, laboratory tests, or electrocardiogram that, in the investigator's opinion, require further examination or treatment, or may interfere with the study procedures or safety
  • 13. Active hepatitis B infection (positive for hepatitis B surface antigen, recurrent/persistent ALT elevation, positive serum HBV DNA, or serum HBV DNA >2 × 10⁵ IU/mL)
  • 6. Receipt of any vaccination within the past 1 month
  • 18. Patients who are pregnant, lactating, or have the potential to become pregnant, or those planning a pregnancy
  • 20. Inability to comply with follow-up assessments due to other reasons
  • 21. Patients deemed by the investigator to be unsuitable for participation in this study

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 30 és 75 év között vagy?

Helyszínek itt: Kína

  • Beijing Tiantan HospitalBeijing, KínaContact: Weiqi ChenRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study. The objective of the study is to evaluate the safety, tolerability and potential preliminary efficacy of ALT001 in the treatment of patients with multiple system atrophy-cerebellar type (MSA-C).

A vizsgálat 2 csoportja

  • Intervention groupA vizsgált kezelés

    Intrathecal administration combined with intravenous administration of ALT001 was given to each MSA patient in the intervention group, with intrathecal administration on days 1, 31 and 61 and intravenous administration on days 2 to 14, 32 to 44±3 and 62 to 74±5, and treatment was given once a day. intrathecal administration: 8 mL sodium chloride injection + ALT001 (130 μg/branch) for intrathecal administration, which was completed in about 5 minutes; intravenous administration: ALT001 (130 μg/branch) was dissolved in 100 ml sodium chloride injection, which was completed in about 30-40 minutes. After completion of the above treatments and 90±7 days of follow-up, all subjects entered the OLE study phase. During this period, all participants were given the option of continuing to receive 3 phases (on Days 91 to 104±7, Days 121 to 134±7, and Days 151 to 164±7) of intravenous ALT001 administration (14 consecutive days of ALT001 130 μg qd i.v. in each phase).

    Kezelés: ALT001

  • No intervention groupNincs vizsgálati kezelés, összehasonlításként

    Each MSA-C patient in the blank control group received only basic treatment with no trial-related treatment. After completion of the above treatments and 90±7 days of follow-up, all subjects entered the OLE study phase. During this period, all participants were given the option of continuing to receive 3 phases (on Days 91 to 104±7, Days 121 to 134±7, and Days 151 to 164±7) of intravenous ALT001 administration (14 consecutive days of ALT001 130 μg qd i.v. in each phase).

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07514923: ki vehet részt
A regiszteradat frissítve
2026. szeptember 9.